CoChat

Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”

Open access
Munier, Francis L., Beck-Popovic, Maja, Chantada, Guillermo L., Cobrinik, David, Kivelä, Tero T., Lohmann, Dietmar, Maeder, Philippe, Moll, Annette C., Carcaboso, Angel Montero, Moulin, Alexandre, Schaiquevich, Paula, Bergin, Ciara, Dyson, Paul J., Houghton, Susan, Puccinelli, Francesco, Vial, Yvan, Gaillard, Marie-Claire, Stathopoulos, Christina · 2019 · Progress in Retinal and Eye Research
Cited by 215

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Retinoblastoma is lethal by metastasis if left untreated, so the primary goal of therapy is to preserve life, with ocular survival, visual preservation and quality of life as secondary aims. Historically, enucleation was the first successful therapeutic approach to decrease mortality, followed over 100 years ago by the first eye salvage attempts with radiotherapy. This led to the empiric delineation of a window for conservative management subject to a "state of metastatic grace" never to be violated. Over the last two decades, conservative management of retinoblastoma witnessed an impressive acceleration of improvements, culminating in two major paradigm shifts in therapeutic strategy. Firstly, the introduction of systemic chemotherapy and focal treatments in the late 1990s enabled radiotherapy to be progressively abandoned. Around 10 years later, the advent of chemotherapy in situ, with the capitalization of new routes of targeted drug delivery, namely intra-arterial, intravitreal and now intracameral injections, allowed significant increase in eye preservation rate, definitive eradication of radiotherapy and reduction of systemic chemotherapy. Here we intend to review the relevant knowledge susceptible to improve the conservative management of retinoblastoma in compliance with the "state of metastatic grace", with particular attention to (i) reviewing how new imaging modalities impact the frontiers of conservative management, (ii) dissecting retinoblastoma genesis, growth patterns, and intraocular routes of tumor propagation, (iii) assessing major therapeutic changes and trends, (iv) proposing a classification of relapsing retinoblastoma, (v) examining treatable/preventable disease-related or treatment-induced complications, and (vi) appraising new therapeutic targets and concepts, as well as liquid biopsy potentiality.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.preteyeres.2019.05.005

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Metadata

Authors
Munier, F. L., Beck-Popovic, M., Chantada, G. L., Cobrinik, D., Kivelä, T. T., Lohmann, D., Maeder, P., Moll, A. C., Carcaboso, A. M., Moulin, A., Schaiquevich, P., Bergin, C., Dyson, P. J., Houghton, S., Puccinelli, F., Vial, Y., Gaillard, M.-C., & Stathopoulos, C.
Venue
Progress in Retinal and Eye Research
Publisher
Elsevier BV
Published
2019-11
Volume
73
Pages
100764
ISSN
1350-9462 (ISSN-L)
OpenAlex
W2948264194
Cited by
215
References
14
FWCI
22.50
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”. https://app.cochat.ai/papers/10.1016/j.preteyeres.2019.05.005
The paper
Munier, F. L., Beck-Popovic, M., Chantada, G. L., Cobrinik, D., Kivelä, T. T., Lohmann, D., Maeder, P., Moll, A. C., Carcaboso, A. M., Moulin, A., Schaiquevich, P., Bergin, C., Dyson, P. J., Houghton, S., Puccinelli, F., Vial, Y., Gaillard, M.-C., & Stathopoulos, C. (2019). Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”. Progress in Retinal and Eye Research. https://doi.org/10.1016/j.preteyeres.2019.05.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.